Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride potently inhibits ROCK1 (IC50 ~140 nM) and ROCK2 (Ki ~300 nM) with >200-fold selectivity over related kinases, impacting cytoskeletal organization and cell proliferation (https://www.apexbt.com/y-27632-dihydrochloride.html). It is highly soluble in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL), enabling flexible experimental design. In vitro, Y-27632 reduces prostatic smooth muscle cell proliferation dose-dependently, and in vivo, it suppresses tumor invasion in mouse models (https://doi.org/10.21203/rs.3.rs-5286472/v1). The compound is an established tool for Rho/ROCK signaling research, including stem cell viability and cancer biology. Product stability requires storage as a solid at ≤4°C, with stock solutions maintained below -20°C for short periods.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases regulating actin cytoskeleton, cell contractility, migration, proliferation, and apoptosis. Aberrant ROCK signaling is implicated in cancer progression, fibrosis, and neurodegeneration (https://l3400.com/index.php?g=Wap&m=Article&a=detail&id=15767). Y-27632 dihydrochloride specifically inhibits ROCK kinases, providing a means to dissect Rho/ROCK pathway functions and develop targeted therapies. Its selectivity minimizes off-target effects compared to older kinase inhibitors. This article extends prior overviews by providing quantitative benchmarks and workflow integration details not found in Strategic Modulation of Rho/ROCK Signaling.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride competitively binds the ATP-binding site of ROCK1 and ROCK2 catalytic domains. This inhibits phosphorylation of downstream targets such as myosin light chain (MLC) and LIM kinase, disrupting actin stress fiber formation and focal adhesion assembly. The compound's IC50 for ROCK1 is 140 nM, and Ki for ROCK2 is 300 nM, with minimal inhibitory activity against PKC, cAMP-dependent protein kinase, MLCK, and PAK (selectivity >200-fold at 10 μM) (A3008 kit). By blocking Rho-mediated signaling, Y-27632 affects cell shape, motility, and cytokinesis. This mechanism underlies its utility in studies of cytoskeletal regulation and tumor cell invasion (https://doi.org/10.21203/rs.3.rs-5286472/v1).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC50 of ~140 nM and ROCK2 with a Ki of 300 nM, demonstrating >200-fold selectivity over PKC, cAMP-dependent protein kinase, MLCK, and PAK at 10 μM (https://www.apexbt.com/y-27632-dihydrochloride.html).
• Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25°C; warming to 37°C or ultrasound enhances dissolution (https://www.apexbt.com/y-27632-dihydrochloride.html).
• Prostatic smooth muscle cell proliferation is reduced in vitro in a dose-dependent manner by Y-27632 (10–100 μM, 24–72 h) (https://doi.org/10.21203/rs.3.rs-5286472/v1).
• In vivo, Y-27632 administration in mouse models (10 mg/kg, intraperitoneal, daily) diminishes tumor invasion and metastasis, with reduced pathological structures (https://doi.org/10.21203/rs.3.rs-5286472/v1).
• Y-27632 enhances stem cell viability and survival during passaging and cryopreservation, supporting regenerative medicine protocols (https://egg-white-lysozyme.com/index.php?g=Wap&m=Article&a=detail&id=6).

This article clarifies dose-response and selectivity data, extending prior summaries such as Advanced Insights into ROCK Inhibition by providing direct solubility and in vivo efficacy benchmarks.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is used in:

• Cell proliferation assays targeting Rho/ROCK pathways in cancer biology.
• Enhancement of stem cell viability and survival during single-cell passaging (https://carmofur.com/index.php?g=Wap&m=Article&a=detail&id=14411).
• Neural and tissue engineering, where cytoskeletal modulation improves graft integration and tissue modeling.
• Investigation of cytokinesis and cell cycle progression by inhibiting stress fiber and contractile ring formation.

Limits and misconceptions are addressed below.

Common Pitfalls or Misconceptions

• Y-27632 is not a broad-spectrum kinase inhibitor; activity is highly selective for ROCK1/2, with minimal effects on PKC, MLCK, or PAK even at high concentrations.
• Long-term storage of Y-27632 solutions leads to degradation; always prepare fresh solutions as needed.
• In vivo effects may vary by model and tissue; not all tumor types respond equivalently to ROCK inhibition.
• Y-27632 does not inhibit bacterial genotoxins such as colibactin; unrelated to microbial toxin neutralization (see Li et al., 2024).
• ROCK inhibition does not universally enhance stem cell differentiation; optimization of conditions is required for each cell type.

This nuanced overview updates and corrects the more general perspective found in Advanced Insights into ROCK Signaling by providing explicit boundaries for compound use.

Workflow Integration & Parameters

Preparation: Dissolve Y-27632 dihydrochloride at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Use gentle warming (37°C) or ultrasonic bath for rapid dissolution. Filter-sterilize if required. Store solid at ≤4°C desiccated; stock solutions at <-20°C for up to several months (avoid repeated freeze-thaw cycles). Avoid storing working solutions for more than a week.

Recommended working concentration: 10–50 μM in cell culture, depending on target cell type and protocol. For in vivo models, published studies use 10 mg/kg/day via intraperitoneal injection (mouse). Always validate dose-response in your specific system.

Controls: Include vehicle (DMSO/ethanol/water) controls and, where possible, use unrelated kinase inhibitors as negative controls to confirm specificity.

Conclusion & Outlook

Y-27632 dihydrochloride is a rigorously benchmarked, highly selective ROCK1/2 inhibitor instrumental for research in cytoskeletal dynamics, stem cell biology, and cancer invasion. Its robust solubility and established dosing parameters enable reproducible results across in vitro and in vivo studies. Continued advances in Rho/ROCK pathway mapping and disease modeling will further expand the compound's translational potential. For detailed product specifications and ordering, refer to the A3008 kit product page.